257 related articles for article (PubMed ID: 12359756)
21. Imatinib mesylate (STI571) interference with growth of neuroectodermal tumour cell lines does not critically involve c-Kit inhibition.
Te Kronnie G; Timeus F; Rinaldi A; Crescenzio N; Spinelli M; Rosolen A; Ricotti E; Basso G
Int J Mol Med; 2004 Sep; 14(3):373-82. PubMed ID: 15289888
[TBL] [Abstract][Full Text] [Related]
22. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
[TBL] [Abstract][Full Text] [Related]
23. Oral imatinib mesylate (STI571/gleevec) improves the efficacy of local intravascular vascular endothelial growth factor-C gene transfer in reducing neointimal growth in hypercholesterolemic rabbits.
Leppänen O; Rutanen J; Hiltunen MO; Rissanen TT; Turunen MP; Sjöblom T; Brüggen J; Bäckström G; Carlsson M; Buchdunger E; Bergqvist D; Alitalo K; Heldin CH; Ostman A; Ylä-Herttuala S
Circulation; 2004 Mar; 109(9):1140-6. PubMed ID: 14769706
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling.
Ischenko I; Camaj P; Seeliger H; Kleespies A; Guba M; De Toni EN; Schwarz B; Graeb C; Eichhorn ME; Jauch KW; Bruns CJ
Oncogene; 2008 Dec; 27(57):7212-22. PubMed ID: 18794807
[TBL] [Abstract][Full Text] [Related]
25. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
26. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer.
Younes MN; Yazici YD; Kim S; Jasser SA; El-Naggar AK; Myers JN
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3425-34. PubMed ID: 16740767
[TBL] [Abstract][Full Text] [Related]
27. Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer.
Han GZ; Liu ZJ; Shimoi K; Zhu BT
Cancer Res; 2005 Jan; 65(2):387-93. PubMed ID: 15695378
[TBL] [Abstract][Full Text] [Related]
28. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class.
Kilic T; Alberta JA; Zdunek PR; Acar M; Iannarelli P; O'Reilly T; Buchdunger E; Black PM; Stiles CD
Cancer Res; 2000 Sep; 60(18):5143-50. PubMed ID: 11016641
[TBL] [Abstract][Full Text] [Related]
29. Delphinidin, a dietary anthocyanidin, inhibits platelet-derived growth factor ligand/receptor (PDGF/PDGFR) signaling.
Lamy S; Beaulieu E; Labbé D; Bédard V; Moghrabi A; Barrette S; Gingras D; Béliveau R
Carcinogenesis; 2008 May; 29(5):1033-41. PubMed ID: 18339683
[TBL] [Abstract][Full Text] [Related]
30. Rhein lysinate suppresses the growth of breast cancer cells and potentiates the inhibitory effect of Taxol in athymic mice.
Lin YJ; Zhen YS
Anticancer Drugs; 2009 Jan; 20(1):65-72. PubMed ID: 19343002
[TBL] [Abstract][Full Text] [Related]
31. Characterization of an imatinib-sensitive subset of high-grade human glioma cultures.
Hägerstrand D; Hesselager G; Achterberg S; Wickenberg Bolin U; Kowanetz M; Kastemar M; Heldin CH; Isaksson A; Nistér M; Ostman A
Oncogene; 2006 Aug; 25(35):4913-22. PubMed ID: 16547494
[TBL] [Abstract][Full Text] [Related]
32. Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants.
McDaid HM; Lopez-Barcons L; Grossman A; Lia M; Keller S; Pérez-Soler R; Horwitz SB
Cancer Res; 2005 Apr; 65(7):2854-60. PubMed ID: 15805287
[TBL] [Abstract][Full Text] [Related]
33. The platelet-derived growth factor receptor as a target for vascular endothelial growth factor-mediated anti-angiogenetic therapy in head and neck cancer.
Bran B; Bran G; Hörmann K; Riedel F
Int J Oncol; 2009 Jan; 34(1):255-61. PubMed ID: 19082496
[TBL] [Abstract][Full Text] [Related]
34. Effects of STI571 (gleevec) on pancreatic cancer cell growth.
Li J; Kleeff J; Guo J; Fischer L; Giese N; Büchler MW; Friess H
Mol Cancer; 2003 Sep; 2():32. PubMed ID: 14521721
[TBL] [Abstract][Full Text] [Related]
35. Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer.
Kim SJ; Uehara H; Yazici S; He J; Langley RR; Mathew P; Fan D; Fidler IJ
Cancer Res; 2005 May; 65(9):3707-15. PubMed ID: 15867366
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice.
Lev DC; Kim SJ; Onn A; Stone V; Nam DH; Yazici S; Fidler IJ; Price JE
Clin Cancer Res; 2005 Jan; 11(1):306-14. PubMed ID: 15671560
[TBL] [Abstract][Full Text] [Related]
37. Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice.
Ng SS; MacPherson GR; Gütschow M; Eger K; Figg WD
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4192-7. PubMed ID: 15217957
[TBL] [Abstract][Full Text] [Related]
38. Imatinib-induced regression of AIDS-related Kaposi's sarcoma.
Koon HB; Bubley GJ; Pantanowitz L; Masiello D; Smith B; Crosby K; Proper J; Weeden W; Miller TE; Chatis P; Egorin MJ; Tahan SR; Dezube BJ
J Clin Oncol; 2005 Feb; 23(5):982-9. PubMed ID: 15572730
[TBL] [Abstract][Full Text] [Related]
39. Structure-activity studies on a library of potent calix[4]arene-based PDGF antagonists that inhibit PDGF-stimulated PDGFR tyrosine phosphorylation.
Zhou H; Wang DA; Baldini L; Ennis E; Jain R; Carie A; Sebti SM; Hamilton AD
Org Biomol Chem; 2006 Jun; 4(12):2376-86. PubMed ID: 16763682
[TBL] [Abstract][Full Text] [Related]
40. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
